Background: Preclinical and observational studies
suggest a relationship between dietary fat intake and breast cancer, but
the association
remains controversial. We carried out a randomized,
prospective, multicenter clinical trial to test the effect of a dietary
intervention designed to reduce fat intake in women
with resected, early-stage breast cancer receiving conventional cancer
management. Methods: A total of 2437 women
were randomly assigned between February 1994 and January 2001 in a
ratio of 40 : 60 to dietary intervention
(n = 975) or control (n = 1462) groups. An interim
analysis was performed after a median follow-up of 60 months when
funding
for the intervention ceased. Mean differences
between dietary intervention and control groups in nutrient intakes and
anthropometric
variables were compared with t tests. Relapse-free survival was examined using Kaplan–Meier analysis, stratified log-rank tests, and Cox proportional hazards
models. Statistical tests were two-sided. Results: Dietary fat intake was lower in the intervention than in the control group (fat grams/day at 12 months, 33.3 [95% confidence
interval {CI} = 32.2 to 34.5] versus 51.3 [95% CI = 50.0 to 52.7], respectively; P<.001), corresponding to a statistically significant (P
= .005), 6-pound lower mean body weight in the intervention group. A
total of 277 relapse events (local, regional, distant,
or ipsilateral breast cancer recurrence or new
contralateral breast cancer) have been reported in 96 of 975 (9.8%)
women in
the dietary group and 181 of 1462 (12.4%) women in
the control group. The hazard ratio of relapse events in the
intervention
group compared with the control group was 0.76 (95%
CI = 0.60 to 0.98, P = .077 for stratified log rank and P = .034 for adjusted Cox model analysis). Exploratory analyses suggested a differential effect of the dietary intervention
based on hormonal receptor status. Conclusions:
A lifestyle intervention reducing dietary fat intake, with modest
influence on body weight, may improve relapse-free survival
of breast cancer patients receiving conventional
cancer management. Longer, ongoing nonintervention follow-up will
address
original protocol design plans, which called for 3
years of follow-up after completion of recruitment.
No comments:
Post a Comment